CANVAS Programme: the effects of Canagliflozin on uric acid and gout in patients with type 2 diabetes
Sodium glucose co-transporter 2 ( SGLT2 ) inhibitors reduce serum urate levels. In a post hoc analysis researchers have investigated the effect of Canagliflozin ( Invokana ) compared to placebo on gout in the CANagliflozin cardioVascular Assessment Study ( CANVAS ) Program.
The CANVAS Program randomly assigned 10,142 participants with type 2 diabetes to Canagliflozin or placebo.
Patients with an adverse event attributed to gout or the need for commencement of a drug for gout were identified and the effects of Canagliflozin compared to placebo were estimated by calculating the hazard ratio ( HR ) and 95% confidence interval ( 95% CI ).
Mean serum urate levels at baseline were 348.2 ( standard deviation 94.3 ) micromol/L in the Canagliflozin group and 349.8 ( 97.1 ) micromol/L in the placebo group.
Serum urate levels were on average 23.3 micromol/L ( 95% CI: -25.4 to -21.3 ) lower in those treated with Canagliflozin compared to placebo during follow-up.
There were 70 individuals who reported an episode of gout and 147 who required commencement of a drug for gout.
The occurrence of gout or the need for treatment for gout was lower in those treated with Canagliflozin compared to placebo ( HR 0.52 95% CI: 0.38 to 0.69 ).
The separate HR for the effect on the risk of gout was 0.58 ( 95% CI: 0.36 to 0.94 ) and for the effect on the need for treatment for gout was 0.52 ( 95% CI: 0.38 to 0.72 ).
In conclusion, Canagliflozin has reduced serum urate levels and the risk of adverse events attributed to gout. ( Xagena )
Source: 55th Annual Meeting of the European Association for the Study of Diabetes ( EASD ), 2019
Rinvoq, an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Rinvoq ( Upadacitinib ), a 15 mg, once-daily oral...
Inrebic for patients with intermediate-2 or high-risk primary or secondary myelofibrosis, approved by FDA
The FDA ( Food and Drug Administration ) has approved Inrebic ( Fedratinib ) for adults with intermediate-2 or high-risk...
DAPA-HF trial: Dapagliflozin significantly reduces both the incidence of cardiovascular death and the worsening of heart failure
Detailed results from the landmark phase III DAPA-HF trial, presented at the ESC Congress 2019, have shown that Dapagliflozin (...
Relapsed and refractory multiple myeloma: European Commission has approved Empliciti plus Pomalidomide and low-dose Dexamethasone
The European Commission ( EC ) has approved Empliciti ( Elotuzumab ) plus Pomalidomide and low-dose Dexamethasone ( EPd )...
Results from a phase 1 study evaluating the pharmacokinetics and safety of a prototype subdermal drug-eluting implant for extended administration...
ESC 2019 - ENTRUST-AF PCI trial: Edoxaban dual therapy noninferior to triple therapy in atrial fibrillation post-stenting
Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in...
Erleada for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease, European Commission approved
The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...
FDA has approved Ofev, first treatment for patients with interstitial lung disease associated with systemic sclerosis or scleroderma
The FDA ( U.S. Food and Drug Administration ) has approved Ofev ( Nintedanib ) capsules to slow the rate...
MONALEESA-3 trial of postmenopausal patients with HR+, HER2- advanced breast cancer treated with Fulvestrant plus Ribociclib
The phase III MONALEESA-3 trial investigated Ribociclib, a cyclin-dependent kinase 4/6 ( CDK4/6 ) inhibitor, plus Fulvestrant as first-line...